BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Pivotal Pipeline | Explore BioAtla's clinical-stage oncology portfolio, featuring promising CAB therapies for solid tumors, with key data readouts expected in 2025 |
Financial Strategy | Delve into BioAtla's cost management efforts and strategic workforce reduction, extending cash runway into 2026 amid clinical development challenges |
Market Positioning | Learn how BioAtla's innovative CAB platform differentiates it in the competitive oncology landscape, balancing potential against established rivals |
Investor Outlook | Analyst price targets range from $1 to $5, reflecting both risks and potential upside as BioAtla approaches critical clinical and partnership milestones |
Metrics to compare | BCAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCABPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −1.5x | −0.5x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | −1.2x | 1.7x | 2.6x | |
Price / LTM Sales | 1.9x | 9.5x | 3.3x | |
Upside (Analyst Target) | - | 319.3% | 43.5% | |
Fair Value Upside | Unlock | 6.6% | 6.8% | Unlock |